UK-based enterprise VR training startup Gemba, used by Coca-Cola, Pfizer, and more, raised an $18M Series A led by Parkway; courses can cost ~$7,250 per person
Paul Sawers / TechCrunch :
Context & Ripple Effects
Gemba's $18M Series A lands in a sector that has been raising steadily since the 2020-21 wave, when Transfr took a $12M Series A and Mursion closed a $20M Series B for workplace-skills training, followed by Interplay's $18M Series B months later. What distinguishes Gemba is its price point — roughly $7,250 per person per course — and a customer roster spanning Coca-Cola and Pfizer.
First-order effects
- The Parkway-led round gives Gemba capital to scale delivery of its premium-priced programs to blue-chip clients like Coca-Cola and Pfizer, where per-seat costs sit far above conventional e-learning.
Second-order effects
- Rivals such as Mursion, Transfr, Interplay, and Talespin now face a funded competitor anchoring enterprise VR training at a four-figure price point, pressuring them to justify their own pricing against immersive outcomes rather than content volume.
Third-order effects
- With Colossyan raising $22M for generative-AI avatar training videos a year later, corporate training is splitting into two cost tiers — high-touch immersive simulation versus cheap AI-generated video — forcing buyers to segment use cases by price and fidelity.
The trend: Enterprise training is consolidating into a funded VR-simulation tier with premium per-seat economics, while generative-AI video emerges as the low-cost alternative competing for the same budgets.